^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Adenocarcinoma
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma

    Published date:
    01/12/2021
    Excerpt:
    ...patients with stage IV EGFR-mutated lung adenocarcinoma who received afatinib containing therapies...afatinib + cetuximab (N=7), or afatinib + bevacizumab (N=2)...A PFS ≥ 6 months on osimertinib (N=5) was associated with a significantly greater PFS on afatinib-containing therapy compared to a PFS < 6 months on osimertinib...Afatinib containing therapies have modest activity in treating patients with EGFR-mutated lung adenocarcinoma after progression on osimertinib...